Latest news with #Hims&HersHealth
Yahoo
2 days ago
- Business
- Yahoo
Why Hims & Hers Health Inc. (HIMS) Went Down On Tuesday
We recently published a list of In this article, we are going to take a look at where Hims & Hers Health Inc. (NYSE:HIMS) stands against other worst-performing stocks. Hims & Hers Health saw its share prices drop by 2.68 percent to close at $53.36 apiece as investors sold off positions amid the lack of catalyst to boost buying appetite. Just recently, Hims & Hers Health Inc. (NYSE:HIMS) announced a new promotion for the blockbuster weight loss drug Wegovy. According to the company, eligible customers are now able to access six months of 'prescription-only' Wegovy at a new and affordable price for $549 per month. The promotion is currently offered for a limited time. It can be learned that Wegovy was among the drugs that Hims & Hers Health Inc. (NYSE:HIMS) created a knockoff version following the supply shortage over the past few years. A nurse in a telehealth platform talking with a patient on video call for consultation. In the first quarter of the year, Hims & Hers Health Inc. (NYSE:HIMS) said net income expanded by 344 percent to $49.48 million from the $11.13 million registered in the same period last year. Revenues increased by 111 percent to $586 million from $278 million year-on-year. Overall, HIMS ranks 10th on our list of worst-performing stocks. While we acknowledge the potential of HIMS, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HIMS and that has 10,000x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
3 Surprising Stocks That Have More Than Doubled in 2025
Hims & Hers Health, FuboTV, and Groupon have all more than doubled in 2025. These companies took very different paths to their stellar year-to-date results. Hims & Hers Health has had to make some major changes to its business in recent months, but it's still positioned for healthy growth. 10 stocks we like better than Hims & Hers Health › This year has had its ups and downs on Wall Street, but some investments are rolling. There are 14 stocks with market caps north of $1 billion that have more than doubled so far in 2025 -- and some of the names will surprise you. Hims & Hers Health (NYSE: HIMS), FuboTV (NYSE: FUBO), and Groupon (NASDAQ: GRPN) -- yes, that Groupon -- are among those 14 stocks that have more than doubled their shareholder money this year. All three have taken entirely different routes to thumping the market this year. After it posted a whopping 183% gain last year, it wouldn't have been shocking to see Hims & Hers Health stock take a breather in 2025. The online healthcare platform that got its start by making it easier for people to secure prescriptions for erectile dysfunction drugs and hair growth treatments blew up last year due to the popularity of its compounded GLP-1 injectables for weight loss. Because Novo Nordisk (NYSE: NVO) was unable to produce Wegovy fast enough to meet surging demand, the Food and Drug Administration put the drug on its official shortage list. That opened up a legal loophole for businesses that operate as compounding pharmacies to produce and sell their own versions of the patented treatment. Hims & Hers cashed in with its own GLP-1 drug, featuring the same active ingredient found in Wegovy and Ozempic -- semaglutide. More importantly, it offered that treatment at more aggressive discounts than Novo Nordisk was putting on the name-brand versions. Hims & Hers Health was doing fine even before it hopped on the GLP-1 bandwagon in spring 2024. Its revenue has risen by at least 65% in each of the last six years. However, the popular new product helped it accelerate its top-line growth in 2024, and it continued to speed up in the first quarter of this year, when revenue more than doubled. This year began with early gains. Late in 2025, incoming President Donald Trump said he would tap Martin Makary to head the FDA. Makary served on the board of a company that also was into GLP-1 compounding, so the market took the view that Hims & Hers' upticks would continue even after Novo Nordisk finished ramping up Wegovy production to a level that could meet patient demand. Matters didn't exactly play out that way. Hims & Hers stock scored an all-time high on Feb. 19, but within weeks, the share price was cut by more than half. Novo Nordisk's production of semaglutide reached the volume necessary to close the FDA loophole, and it seemed as if the semaglutide compounding ride was ending for Hims & Hers and its peers. Then, two things happened that brought investors back. Novo Nordisk cut deals with a small number of telehealth companies, including Hims & Hers, giving them the right to sell discounted monthly subscriptions of Wegovy. Hims & Hers also reported a blowout first quarter earlier this month, and management forecast that the balance of its business outside of compounding would still grow at a healthy 30% clip this year. One of the first stocks to double in 2025 was FuboTV. The company behind the namesake sports-centric live TV streaming service more than tripled in the first week of trading after it struck a transformative deal with Disney (NYSE: DIS). Fubo had just 1.7 million paid subscribers heading into this year, less than 10% of the roughly 20 million households paying for live TV streaming services that digitally recreate versions of the familiar cable or satellite TV bundle. The stock entered this year trading 98% below the peak it touched in late 2020, when management had dreams of turning the company into a streaming platform with an online sportsbook component. Fubo had to fold that hand, but it still had an ace up its sleeve. Disney and two other media giants had been hoping to launch Venu Sports, a monthly subscription service that would bundle content from all of their sports properties -- anchored by Disney's majority-owned ESPN -- into a digital subscription costing $43 a month. But Fubo sued, and last summer, it won an injunction blocking Venu's launch. In a move to clear that obstacle, Disney offered to acquire a 70% stake in FuboTV. The House of Mouse will contribute its larger Hulu + Live TV service -- with 4.6 million subscribers -- to Fubo. Fubo will also receive $220 million from the Venu partners in exchange for dropping its lawsuit. The deal with Disney isn't expected to close until the the first half of next year, but if it falls apart, Fubo would collect another $130 million. It also has access to a $145 million term loan from Disney. Then something amusing happened. Within days of the deal that would give Disney a majority stake in Fubo but keep the smaller company's management in control, the three Venu partners decided not to go through with their digital bundle. Fubo has had its share of growing pains, but it's in an interesting win-win situation here. However, the shares have been meandering along at levels well below those they reached during that initial spike in January. Finally, we have a more conventional doubling chart. Groupon's rise this year can be traced to two specific events: the fourth-quarter earnings report it delivered in early March, and the first-quarter report it released earlier this month. After eight consecutive years of declining revenues, the online discounter of local experiences is starting to turn the corner. Revenue did decline 5% in Q4 2024, but gross billings for its flagship North American business climbed 8%. Its latest report showed even more improvement. Groupon posted a strong and unexpected profit. Analysts now predict it will make a return to revenue growth this year, and that its improvements will accelerate in 2026. Its business model could also prove to be attractive to lead-seeking businesses if the U.S. economy loses steam -- so don't discount this discounter. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Rick Munarriz has positions in Walt Disney. The Motley Fool has positions in and recommends Walt Disney and fuboTV. The Motley Fool has a disclosure policy. 3 Surprising Stocks That Have More Than Doubled in 2025 was originally published by The Motley Fool
Yahoo
4 days ago
- Business
- Yahoo
Why Hims & Hers Health Inc. (HIMS) Went Down On Tuesday
We recently published a list of In this article, we are going to take a look at where Hims & Hers Health Inc. (NYSE:HIMS) stands against other worst-performing stocks. Hims & Hers Health saw its share prices drop by 2.68 percent to close at $53.36 apiece as investors sold off positions amid the lack of catalyst to boost buying appetite. Just recently, Hims & Hers Health Inc. (NYSE:HIMS) announced a new promotion for the blockbuster weight loss drug Wegovy. According to the company, eligible customers are now able to access six months of 'prescription-only' Wegovy at a new and affordable price for $549 per month. The promotion is currently offered for a limited time. It can be learned that Wegovy was among the drugs that Hims & Hers Health Inc. (NYSE:HIMS) created a knockoff version following the supply shortage over the past few years. A nurse in a telehealth platform talking with a patient on video call for consultation. In the first quarter of the year, Hims & Hers Health Inc. (NYSE:HIMS) said net income expanded by 344 percent to $49.48 million from the $11.13 million registered in the same period last year. Revenues increased by 111 percent to $586 million from $278 million year-on-year. Overall, HIMS ranks 10th on our list of worst-performing stocks. While we acknowledge the potential of HIMS, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HIMS and that has 10,000x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23-05-2025
- Business
- Yahoo
Why Hims & Hers Health (HIMS) Stock Is Falling Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth division introduced a monthly $200 price cap for weight-loss medications such as Wegovy and Zepbound, a move that could significantly disrupt pricing in the weight loss drug market. For Hims & Hers, which offers both compounded Semaglutide and branded GLP-1 treatments, this introduces a direct competitive threat, particularly if Evernorth's pricing becomes a benchmark in the industry. The shares closed the day at $53.52, down 7.7% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Hims & Hers Health? Access our full analysis report here, it's free. Hims & Hers Health's shares are extremely volatile and have had 94 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 16 days ago when the stock gained 20.2% on the news that the company reported strong first quarter 2025 results which significantly beat analysts' expectations on revenue, EPS, and EBITDA. Sales more than doubled from the previous year driven by higher monthly spending per subscriber and a broader product mix tailored to personalized health needs. While subscriber growth slowed to 38% year over year, average revenue per user climbed over 50%, indicating deeper wallet share from existing customers and more engagement with premium offerings. On the other hand, revenue guidance was softer than anticipated. Still, we think this was a decent quarter. Hims & Hers Health is up 112% since the beginning of the year, but at $53.35 per share, it is still trading 22.4% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health's shares 5 years ago would now be looking at an investment worth $5,340. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
22-05-2025
- Health
- Yahoo
Hims & Hers Introduces 6-Month Wegovy® New Customer Offer
SAN FRANCISCO, May 22, 2025--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. "We are always looking for long-term, sustainable ways to increase access to care for our customers," said Andrew Dudum, CEO and co-founder of Hims & Hers. "This is another example of how we're working together with the industry to bring people closer to the care and treatments they need." Starting today, new customers eligible for Wegovy® on the Hims & Hers platform can access their care for $549 per month for 6 months (for a limited-time only)1, ensuring customers have a longer window to access the affordable care they need. Included in that price is access to Hims & Hers' world-class, holistic approach to weight loss, powered by today's technology. Hims & Hers will continue to offer access to its full breadth of weight loss treatment options, including other medications, oral kits, protein, nutrition kits, and clinically-backed care plans, all of which help customers start and sustain their health journey based on their needs, goals, and eligibility. For more information, visit About Hims & Hers Health, Inc Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit and 1 Promo ends 6/30/25. New Wegovy®, first-order customers only, paid up front in full. Savings vary by plan purchase. Discount based on Wegovy® average monthly retail price (w/o insurance). Standard rates resume after promo period: $649/mo (3-mo), $599/mo (6-mo). Auto-renews at standard rates unless canceled 2 days before billing. Rx required. Terms apply. Not available in all 50 states. Weight Loss by Hims & Hers is a holistic program that includes nutrition support, technological tools, and medications prescribed based on what your provider determines is medically appropriate and necessary for you. See website for full details, important safety information, and restrictions, including online provider consultation requirements. View source version on Contacts Press Contact Abby Reisinger-Moleypress@
